Arena Pharmaceuticals, Inc. (ARNA) Reaches $21.15 After 8.00% Down Move; Hutchin Hill Capital LP Has Raised Its Las Vegas Sands (LVS) Position

August 8, 2017 - By test

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a huge mover today! About 555,507 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since August 8, 2016 and is downtrending. It has underperformed by 28.62% the S&P500.The move comes after 9 months negative chart setup for the $804.23 million company. It was reported on Aug, 8 by Barchart.com. We have $19.46 PT which if reached, will make NASDAQ:ARNA worth $64.34 million less.

Hutchin Hill Capital Lp increased Las Vegas Sands Corp (LVS) stake by 156.46% reported in 2016Q4 SEC filing. Hutchin Hill Capital Lp acquired 16,594 shares as Las Vegas Sands Corp (LVS)’s stock rose 9.11%. The Hutchin Hill Capital Lp holds 27,200 shares with $1.45M value, up from 10,606 last quarter. Las Vegas Sands Corp now has $48.35B valuation. The stock rose 0.05% or $0.03 reaching $61.1 per share. About 1.06M shares traded. Las Vegas Sands Corp. (NYSE:LVS) has risen 28.09% since August 8, 2016 and is uptrending. It has outperformed by 11.39% the S&P500.

Since May 12, 2017, it had 1 buy, and 0 insider sales for $29,750 activity. 25,000 shares were bought by Munshi Amit, worth $29,750 on Friday, May 12.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $804.23 million. The Firm is focused on developing small molecule drugs across a range of therapeutic areas. It currently has negative earnings. The Firm has three primary investigational clinical programs: etrasimod in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on August, 14. They expect $-0.68 EPS, up 38.18% or $0.42 from last year’s $-1.1 per share. After $-0.90 actual EPS reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -24.44% EPS growth.

Investors sentiment increased to 1.97 in 2016 Q4. Its up 0.79, from 1.18 in 2016Q3. It increased, as 9 investors sold Arena Pharmaceuticals, Inc. shares while 25 reduced holdings. 19 funds opened positions while 48 raised stakes. 110.93 million shares or 6.74% less from 118.95 million shares in 2016Q3 were reported. Principal Gp holds 0% or 44,702 shares in its portfolio. Next Fincl has 0% invested in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Prelude Capital Mgmt Ltd Llc holds 0.01% of its portfolio in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) for 33,700 shares. D E Shaw Inc invested 0% in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Clearbridge Investments Limited Liability has 22,560 shares for 0% of their portfolio. National Planning owns 15,450 shares or 0% of their US portfolio. California Pub Employees Retirement Sys holds 0% or 518,400 shares. Janus Cap Limited Company holds 0% in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) or 13,855 shares. Natl Bank Of America Corporation De holds 0% or 47,712 shares in its portfolio. Aperio Grp Inc Limited Liability Com reported 0% stake. Legal And General Grp Plc accumulated 0% or 77,752 shares. Ascend Limited Liability invested in 1.83M shares. Blackrock Limited Liability Com accumulated 252,054 shares or 0% of the stock. Gp One Trading Ltd Partnership holds 0.01% in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) or 516,553 shares. Lpl Financial Limited Company owns 12,000 shares for 0% of their portfolio.

Among 6 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Arena Pharmaceuticals had 11 analyst reports since October 28, 2015 according to SRatingsIntel. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Buy” rating by Citigroup on Wednesday, July 12. On Wednesday, October 28 the stock rating was maintained by WallachBeth Capital with “Buy”. RBC Capital Markets maintained it with “Sector Perform” rating and $2 target in Wednesday, November 11 report. The firm has “Outperform” rating given on Thursday, September 15 by FBR Capital. As per Wednesday, July 19, the company rating was maintained by Cantor Fitzgerald. Leerink Swann maintained the stock with “Buy” rating in Monday, July 17 report. As per Tuesday, July 11, the company rating was maintained by Cantor Fitzgerald. As per Thursday, June 29, the company rating was maintained by Cantor Fitzgerald.

Hutchin Hill Capital Lp decreased Parsley Energy Inc (NYSE:PE) stake by 34,000 shares to 855,000 valued at $30.13M in 2016Q4. It also reduced Astoria Finl Corp (NYSE:AF) stake by 1.15M shares and now owns 150,000 shares. Fresh Del Monte Produce Inc (NYSE:FDP) was reduced too.

Investors sentiment increased to 1.53 in 2016 Q4. Its up 0.40, from 1.13 in 2016Q3. It improved, as 36 investors sold LVS shares while 137 reduced holdings. 98 funds opened positions while 167 raised stakes. 296.26 million shares or 5.17% less from 312.41 million shares in 2016Q3 were reported. Community Tru And Invest Company owns 4,000 shares for 0.03% of their portfolio. Riverpark Advsrs Ltd Liability Com holds 141,796 shares. Argent Capital Ltd has 0.75% invested in Las Vegas Sands Corp. (NYSE:LVS). Highland Mgmt Limited Com invested in 5,025 shares. Gabelli Funds Ltd Liability Company holds 0.11% or 359,500 shares. Hennessy Advsr stated it has 0.14% of its portfolio in Las Vegas Sands Corp. (NYSE:LVS). Banced holds 0.71% in Las Vegas Sands Corp. (NYSE:LVS) or 7,029 shares. Blackrock Institutional Na stated it has 9.63 million shares. First Quadrant Limited Partnership Ca holds 0.01% or 6,000 shares. Polar Asset Ptnrs invested 0.3% of its portfolio in Las Vegas Sands Corp. (NYSE:LVS). Commerzbank Aktiengesellschaft Fi holds 0.06% or 79,212 shares in its portfolio. Millennium Management Ltd Liability Com invested 0.08% in Las Vegas Sands Corp. (NYSE:LVS). Swiss Bank has 0.1% invested in Las Vegas Sands Corp. (NYSE:LVS) for 1.22 million shares. Franklin Street Advisors Nc, a North Carolina-based fund reported 77,047 shares. Summit Lc invested in 0.07% or 5,600 shares.

Among 18 analysts covering Las Vegas Sands (NYSE:LVS), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Las Vegas Sands had 45 analyst reports since July 23, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Las Vegas Sands Corp. (NYSE:LVS) on Thursday, July 23 with “Buy” rating. The stock of Las Vegas Sands Corp. (NYSE:LVS) has “Hold” rating given on Thursday, August 20 by Vetr. The stock of Las Vegas Sands Corp. (NYSE:LVS) has “Market Perform” rating given on Friday, November 4 by Telsey Advisory Group. As per Friday, July 28, the company rating was maintained by Barclays Capital. On Monday, May 1 the stock rating was maintained by Susquehanna with “Buy”. Stifel Nicolaus maintained Las Vegas Sands Corp. (NYSE:LVS) rating on Monday, July 3. Stifel Nicolaus has “Buy” rating and $6600 target. The firm has “Neutral” rating given on Tuesday, August 18 by Goldman Sachs. The firm has “Buy” rating given on Wednesday, April 13 by Citigroup. The firm has “Buy” rating by Aegis Capital given on Thursday, March 23. The rating was upgraded by Vetr to “Sell” on Wednesday, August 12.